LFMD_OUT_1 [2025-04-29 09:47:00 -0400] 5443 Bytes | 1468 tokens | Cum: 1468 tkns (18.35% of 8k)
==========================================================================

Good morrow, traveler. 'Tis 9:46 AM on Tue Apr 29, 2025, and lo, LifeMD (LFMD) hath gained ground from $6.10 unto $7.32. Shall we seize upon this chance, or tarry and watch?

--- COMPANY PROFILE ---
Company: LifeMD (LFMD)
IPO: 2020-12-10 (4 Years Ago)
Market Cap: $240,528,997
Shares Outstanding: 44,580,000
Industry: SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE
Exchange: XNAS
Description: LifeMD Inc is a direct-to-patient telehealth company that provides a smarter, cost-effective, and more convenient way of accessing comprehensive, virtual healthcare. Its telehealth platform seamlessly integrates a clinician-centric electronic medical record (EMR) system, proprietary algorithms for case-load balancing and scheduling, customer relationship management functionality, remote and in-home lab testing, and digital prescription capabilities, patient-provider audio/video interfacing, cloud pharmacy fulfillment, and more. In addition to telehealth offerings, the company sells nutritional supplements and other over-the-counter products. The company has two operating segments: Telehealth and WorkSimpli. The company generates the majority of its revenue from the Telehealth segment.

Here’s a list of headlines for LifeMD:

Today 08:05AM - LifeMD Announces Plans to Expand Affordable Access to Wegovy for Cash-Pay Patients
Apr-28-25 04:05PM - Medifast Announces First Quarter 2025 Financial Results
Apr-28-25 04:05PM 04:05PM - LifeMD to Report First Quarter 2025 Financial Results on May 6
Apr-28-25 04:05PM 08:00AM - LifeMD Acquires Women's Health Provider Optimal Human Health MD to Accelerate Entry into the Women's Health Market
Apr-21-25 12:52PM - LifeMD, Inc. (LFMD): A Bull Case Theory
Apr-17-25 08:00AM - LifeMD Expands Insurance Acceptance to Medicare Beneficiaries for Qualifying Virtual Primary Care, Including in its Weight Loss Programs
Apr-14-25 04:05PM - Medifast to Announce Financial Results for the First Quarter Ended March 31, 2025
Apr-09-25 08:51AM - Agilon (AGL) Moves 26.1% Higher: Will This Strength Last?
Apr-08-25 10:10AM - LifeMD Is Back To Life
Apr-01-25 04:15PM - Hims Stock Jumps After Adding Eli Lilly's Obesity Drug To Its Platform
Apr-01-25 04:15PM 04:02PM - Hims Stock Jumps After Inking Deal To Sell Eli Lilly's Obesity Drug, Zepbound
Apr-01-25 04:15PM 02:30PM - Hims Stock Rockets After Inking Deal To Sell Eli Lilly's Obesity Drug, Zepbound
Mar-31-25 08:00AM - LifeMD to Participate in the 24th Annual Needham Virtual Healthcare Conference
Mar-28-25 09:21AM - Medifast: GLP-1 Caused A Vicious MLM Flywheel Effect
Mar-25-25 04:05PM - LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
Mar-11-25 03:02AM - LifeMD Inc (LFMD) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic Expansions
Mar-10-25 05:30PM - LifeMD Reports Fourth Quarter 2024 Results
Mar-07-25 07:06AM - LifeMD Inc (LFMD) Q4 2024: Everything You Need to Know Ahead of Earnings
Mar-06-25 08:00AM - LifeMD Announces Integration with LillyDirect Pharmacy Provider to Offer Patients Streamlined Access to Branded Dual GLP-1/GIP Zepbound
Mar-05-25 08:00AM - LifeMD to Participate in the KeyBanc Capital Markets Healthcare Forum
Feb-25-25 08:05AM - LifeMD to Report Fourth Quarter 2024 Financial Results on March 10
Feb-24-25 08:05AM - LifeMD Announces Entry Into the Behavioral Health Market

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-03-31T12:00:00Z - LifeMD to Participate in the 24th Annual Needham Virtual Healthcare Conference
B2 - 2025-03-25T20:05:00Z - LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
B3 - 2025-03-10T21:30:00Z - LifeMD Reports Fourth Quarter 2024 Results
B4 - 2025-01-28T13:00:00Z - LifeMD to Participate in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
B5 - 2024-12-24T13:00:00Z - LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
B6 - 2024-09-24T20:05:00Z - LifeMD® Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for LifeMD (LFMD).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

LFMD_OUT_3 [2025-04-29 09:47:01 -0400] 766 Bytes | 214 tokens | Cum: 1684 tkns (21.05% of 8k)
==========================================================================

Showing B3 (chunk 1 of 1): B3:
**LifeMD Reports Fourth Quarter 2024 Results**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/03/10/3040216/6480/en/LifeMD-Reports-Fourth-Quarter-2024-Results.htmlLifeMD reported strong financial results for Q4 2024, with telehealth revenue up 60% and adjusted EBITDA increasing 78% to $9 million. The company also provided guidance for 2025, expecting consolidated revenue of $265-$275 million and adjusted EBITDA of $30-$32 million.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

LFMD_OUT_5 [2025-04-29 09:47:03 -0400] 984 Bytes | 290 tokens | Cum: 1976 tkns (24.70% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-29T12:31:41Z - LifeMD Announces Plans to Expand Affordable Access to Wegovy® for Cash-Pay Patients | Taiwan News | ...
A2 - 2025-04-29T12:07:23Z - 12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Cyclacel Pharmaceuticals (NASDAQ:CYCC...
A3 - 2025-04-29T12:17:27Z - LifeMD Announces Plans to Expand Affordable Access to Wegovy® for Cash-Pay Patients...
A4 - 2025-04-28T20:23:53Z - LifeMD to Report First Quarter 2025 Financial Results on May 6...
A5 - 2025-04-28T20:12:41Z - LifeMD to Report First Quarter 2025 Financial Results on May 6 | Taiwan News | Apr. 29, 2025 04:05...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

LFMD_OUT_7 [2025-04-29 09:47:04 -0400] 1185 Bytes | 313 tokens | Cum: 2291 tkns (28.64% of 8k)
==========================================================================

Showing A1 (chunk 1 of 8): A1:
**LifeMD Announces Plans to Expand Affordable Access to Wegovy® for Cash-Pay Patients | Taiwan News | Apr. 29, 2025 20:05**Date: 2025-04-29Source: {'uri': 'taiwannews.com.tw', 'dataType': 'news', 'title': 'Taiwan News'}URL: https://taiwannews.com.tw/en/news/6097742NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announced plans to offer broad, affordable, and streamlined access to Wegovy® (semaglutide) through NovoCare® Pharmacy. This integration offers a simplified pathway for cash-pay patients to access all FDA-approved dose strengths of Wegovy® directly within LifeMD's virtual care platform.

LifeMD's weight management program is one of the fastest-growing cash-pay offerings in the country, delivering virtual consultations, lab testing, diet and lifestyle support, and prescriptions to anti-obesity medica

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

LFMD_OUT_9 [2025-04-29 09:47:05 -0400] 1186 Bytes | 264 tokens | Cum: 2557 tkns (31.96% of 8k)
==========================================================================

Showing A1 (chunk 2 of 8): tions including GLP-1s when clinically appropriate, within a single, tech-enabled platform. The addition of direct access to Wegovy® through NovoCare® Pharmacy enhances LifeMD's ability to support patients with a brand-name GLP-1 option at a recently reduced self-pay cost of $499 per month, including convenient home delivery.

"Working with NovoCare® Pharmacy represents a meaningful step forward for LifeMD's weight management program," said Justin Schreiber, Chairman and CEO of LifeMD. "By embedding direct access to Wegovy® via NovoCare® Pharmacy into our platform, we're enhancing the patient experience, expanding access to a critical medication, and reinforcing LifeMD's position as a leader in delivering comprehensive, technology-enabled obesity care. With this offering, we've taken another important step in delivering on our promise of reducing friction in the patient journey -- ensuri

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

LFMD_OUT_11 [2025-04-29 09:47:05 -0400] 1185 Bytes | 246 tokens | Cum: 2805 tkns (35.06% of 8k)
==========================================================================

Showing A1 (chunk 3 of 8): ng more patients can access life-changing medications like Wegovy® without unnecessary delays or barriers."

This offering reflects the growing demand among cash-pay patients for convenient access to clinically backed FDA-approved obesity treatment options. With an end-to-end digital care experience and vertically integrated infrastructure -- including a 50-state affiliated medical group and national diagnostic lab partnerships -- LifeMD is uniquely positioned to deliver branded GLP-1 therapies at scale.

Wegovy® is the first GLP-1 therapy approved in the United States for both chronic weight management and cardiovascular risk reduction in adults with obesity. Through this offering, all doses of Wegovy® are available in a pen device to eligible LifeMD patients who are uninsured or whose insurance does not cover prescription weight-loss medications.

About LifeMD, Inc.

LifeMD® is a leadi

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

LFMD_OUT_13 [2025-04-29 09:47:06 -0400] 1181 Bytes | 265 tokens | Cum: 3072 tkns (38.40% of 8k)
==========================================================================

Showing A1 (chunk 4 of 8): ng provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men's and women's health, weight management, and hormone therapy. The Company leverages a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a 22,500-square-foot affiliated pharmacy, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information, please visit LifeMD.com.

Cautionary Note Regarding Forward Looking Statements

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

LFMD_OUT_15 [2025-04-29 09:47:07 -0400] 1181 Bytes | 255 tokens | Cum: 3329 tkns (41.61% of 8k)
==========================================================================

Showing A1 (chunk 5 of 8): Forward-looking statements contained in this news release may be identified by the use of words such as: "believe," "expect," "anticipate," "project," "should," "plan," "will," "may," "intend," "estimate," "predict," "continue," and "potential," or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.

Forward-

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

LFMD_OUT_17 [2025-04-29 09:47:08 -0400] 1181 Bytes | 238 tokens | Cum: 3569 tkns (44.61% of 8k)
==========================================================================

Showing A1 (chunk 6 of 8): looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, "Risk Factors" identified in our filings with the Securities and E

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

LFMD_OUT_19 [2025-04-29 09:47:09 -0400] 1181 Bytes | 253 tokens | Cum: 3824 tkns (47.80% of 8k)
==========================================================================

Showing A1 (chunk 7 of 8): xchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.

Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.

Investor Contact:

Marc Benathen, Chief Financial Officer

[email protected]

Media Contact:

Jessica Friedeman, Chief Marketing

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

LFMD_OUT_21 [2025-04-29 09:47:09 -0400] 310 Bytes | 89 tokens | Cum: 3915 tkns (48.94% of 8k)
==========================================================================

Showing A1 (chunk 8 of 8): Officer

[email protected]

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

LFMD_OUT_23 [2025-04-29 09:47:11 -0400] 533 Bytes | 142 tokens | Cum: 4059 tkns (50.74% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-04-28 8-K Item 7.01 Regulation FD Disclosure .

On April 25, 2025, LifeMD, Inc. (the Company), entered into and closed on an Asset Purchase Agrmt (the Purchase Agrmt), by and among the Company; OHHMD, PLLC (Seller), a North Carolina professional limited liability company; Doug Luc...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

LFMD_OUT_25 [2025-04-29 09:47:12 -0400] 1181 Bytes | 287 tokens | Cum: 4348 tkns (54.35% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 7.01 Regulation FD Disclosure .

On April 25, 2025, LifeMD, Inc. (the Company), entered into and closed on an Asset Purchase Agreement (the Purchase Agreement), by and among the Company; OHHMD, PLLC (Seller), a North Carolina professional limited liability company; Doug Lucas, DO, the sole member of OHHMD; and the Companys affiliate LifeMD Southern Patient Medical Care, P.C., a Florida professional corporation (PC Purchaser).

Pursuant to the Purchase Agreement, the Company acquired key assets from Optimal Human Health MD, a nationwide womens health virtual care provider, that are used in the operation of, or related to, a virtual clinical practice focusing on womens health and hormone replacement therapies (the Business). The Company acquired the assets in exchange for 100,000 shares of the Companys common stock, par value $0.01 per share, with 50,000 of those shares issued a

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

LFMD_OUT_27 [2025-04-29 09:47:13 -0400] 1181 Bytes | 261 tokens | Cum: 4611 tkns (57.64% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): t closing, and 50,000 of those shares issued on the first anniversary of closing, and other nominal consideration.

In addition, pursuant to the Purchase Agreement, the Company agreed to make payments to Seller, contingent upon the achievement of certain milestones through the second anniversary of closing, if and when the Business reaches and maintains certain levels of active patients with accompanying quarterly revenue (the Earn Out Consideration). The Earn-Out Consideration would consist of 100,000 shares of the Companys common stock, issued on the second anniversary of closing, if the Business reaches 2,500 active patients with an accompanying quarterly revenue of at least $2,500,000 and maintains this level for at least six full and consecutive calendar months on or prior to the eighteen-month anniversary of closing; and (ii) 100,000 shares of the Companys common stock, issued on

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

LFMD_OUT_29 [2025-04-29 09:47:14 -0400] 1181 Bytes | 248 tokens | Cum: 4861 tkns (60.76% of 8k)
==========================================================================

Showing S1 (chunk 3 of 6): the second anniversary of closing if the Business reaches 5,000 active patients with an accompanying quarterly revenue of at least $4,500,000 and maintains this level for at least six full and consecutive calendar months on or prior to the second anniversary of closing.

In connection with the Purchase Agreement, PC Purchaser entered into a three-year employment agreement with Dr. Lucas, who will serve as the Companys Vice President, Female Health Clinical Operations, with the third year of employment on an at-will basis (the Employment Agreement). Employment offers were also accepted by at least 75% of Sellers employees and independent contractors.

The Purchase Agreement and Employment Agreement contain customary representations, warranties and covenants by each of the parties, and contain indemnification provisions under which the parties have agreed, subject to certain limitations,

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

LFMD_OUT_31 [2025-04-29 09:47:15 -0400] 1181 Bytes | 260 tokens | Cum: 5123 tkns (64.04% of 8k)
==========================================================================

Showing S1 (chunk 4 of 6): to indemnify each other against certain liabilities.

On April 28, 2025, the Company issued a press release announcing its entry into the Purchase Agreement. A copy of the Companys press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

By filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD. The information contained in the Presentation is summary information that is intended to be considered in the context of the Companys Securities and Exchange Commission (SEC) filings and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the informatio

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

LFMD_OUT_33 [2025-04-29 09:47:16 -0400] 1181 Bytes | 260 tokens | Cum: 5385 tkns (67.31% of 8k)
==========================================================================

Showing S1 (chunk 5 of 6): n contained in this report, although it may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure.

The information provided under this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any Company filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as shall be expressly set forth by specific reference in such filing.

Cautionary Statements Regarding Forward-Looking Information

Certain statements contained in this report that are not statements of historical fact constitute forward-looking statements within the

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

LFMD_OUT_35 [2025-04-29 09:47:17 -0400] 790 Bytes | 178 tokens | Cum: 5565 tkns (69.56% of 8k)
==========================================================================

Showing S1 (chunk 6 of 6): meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, certain plans, expectations, goals, projections and benefits relating to the acquisition of the Business, which are subject to numerous assumptions, risks and uncertainties. Words such as anticipates, believes, estimates, expects, if, likely, intends, will, would and other similar expressions are intended to identify forward-looking statements but are not the exclusive means of identifyi...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

LFMD_OUT_37 [2025-04-29 09:47:24 -0400] 7660 Bytes | 2165 tokens | Cum: 7732 tkns (96.65% of 8k)
==========================================================================

This is our set of metrics for LifeMD.
Please analyze the numbers.

+-------------------+-----------------------+-------------------------+------------------------+
| Volume: 5,019,403 | Perf Month: 34.86% | Option/Short: Yes / Yes | Sales Y/Y TTM: 39.27% |
+-------------------+-----------------------+-------------------------+------------------------+
| Avg Volume: 1.22M | Perf Quarter: 33.64% | Short Float: 17.45% | ROE: - |
+-------------------+-----------------------+-------------------------+------------------------+
| Rel Volume: 78.19 | Index: RUT | Short Ratio: 5.04 | ROI: -206.17% |
+-------------------+-----------------------+-------------------------+------------------------+
| RSI (14): 75.79 | Market Cap: 327.69M | Short Interest: 6.17M | Sales Surprise: 11.80% |
+-------------------+-----------------------+-------------------------+------------------------+
| ATR (14): 0.52 | Shs Outstand: 42.19M | Beta: 2.26 | EPS Surprise: 61.09% |
+-------------------+-----------------------+-------------------------+------------------------+
| SMA20: 33.98% | Shs Float: 35.36M | Sales Q/Q: 43.23% | P/E: - |
+-------------------+-----------------------+-------------------------+------------------------+
| SMA50: 31.60% | Inst Own: 36.51% | Sales past 5Y: 88.75% | Earnings: Mar 10 AMC |
+-------------------+-----------------------+-------------------------+------------------------+
| SMA200: 33.27% | Insider Own: 20.68% | Employees: 336 | |
+-------------------+-----------------------+-------------------------+------------------------+
| Perf Week: 30.09% | Insider Trans: -1.39% | Debt/Eq: - | |
+-------------------+-----------------------+-------------------------+------------------------+

The next section covers any insider trading by LifeMD officers or majority shareholders (if available).

Inside Trans: LifeMD, Inc. (LFMD) by STAN MARIA E. (Chief Accounting Officer) on 2025-03-31
- Common Stock: 9375 shares at $0 (D)
- Common Stock: 10000 shares at $0 (D)
- Common Stock: 40000 shares at $0 (D)
- Common Stock: 40000 shares at $0 (D)
- Common Stock: 20000 shares at $0 (D)
- Common Stock: 20000 shares at $0 (D)

Inside Trans: LifeMD, Inc. (LFMD) by Alvarez Nicholas P (Chief Acquisition Officer) on 2025-03-31
- Common Shares: 75000 shares at $0 (D)

Inside Trans: LifeMD, Inc. (LFMD) by Yecies Eric Harold (Chief Legal Officer & GC) on 2025-03-31
- Common Stock: 18750 shares at $0 (D)
- Common Stock: 30000 shares at $0 (D)

Inside Trans: LifeMD, Inc. (LFMD) by Wijnker Dennis (Chief Technology Officer) on 2025-03-31
- Common Stock: 25000 shares at $0 (D)

Inside Trans: LifeMD, Inc. (LFMD) by Galluppi Stefan (Chief Innovation Officer) on 2025-03-31
- Common Stock: 30000 shares at $0 (D)

Inside Trans: LifeMD, Inc. (LFMD) by Benathen Marc David (Chief Financial Officer) on 2025-03-31
- Common Stock: 75000 shares at $0 (D)

Inside Trans: LifeMD, Inc. (LFMD) by Schreiber Justin (Chairman and CEO) on 2025-03-19
- Common Stock: 27994 shares at $0 (I)
- Common Stock: 13997 shares at $0 (I) Footnote: This transaction involved the reporting person's gift of 13,997 shares of LFMD common stock to Child 1.
- Common Stock: 13997 shares at $0 (I) Footnote: This transaction involved the reporting person's gift of 13,997 shares of LFMD common stock to Child 2.

Inside Trans: LifeMD, Inc. (LFMD) by FRIEDEMAN JESSICA (Chief Marketing Officer) on 2025-03-14
- Common Stock: 30000 shares at $5.6555 (D)

Inside Trans: LifeMD, Inc. (LFMD) by Alvarez Nicholas P (Chief Acquisition Officer) on 2025-03-07
- Common Shares: 100000 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 212453838.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -18728498.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 7.32
Average Volume: 950390.33
30-Day High: 7.32
30-Day Low: 4.82

[Detailed Financials: TTM 2024]
- Total Assets: $72,460,026.00
- Total Liabilities: $76,505,394.00
- Total Equity: $-4,045,368.00
- Current Assets: $48,733,089.00
- Current Liabilities: $60,255,145.00

[Income Statement: TTM 2024]
- Revenue: $212,453,838.00
- Net Income: $-18,728,498.00
- Gross Profit: $188,385,359.00
- Operating Income: $-16,144,681.00
- Earnings Per Share (EPS): N/A

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $1,858,199.00

[Detailed Financials: FY 2024]
- Total Assets: $72,460,026.00
- Total Liabilities: $76,505,394.00
- Total Equity: $-4,045,368.00
- Current Assets: $48,733,089.00
- Current Liabilities: $60,255,145.00

[Income Statement: FY 2024]
- Revenue: $212,453,838.00
- Net Income: $-18,728,498.00
- Gross Profit: $188,385,359.00
- Operating Income: $-16,144,681.00
- Earnings Per Share (EPS): N/A

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $1,858,199.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of LifeMD (LFMD).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about LifeMD.

2) MARKET_SCORE[]
This conversation was initiated because LFMD is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for LFMD.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, LFMD could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect LFMD to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of LifeMD.

11) ETHICAL_RATING[]
Rate LifeMD’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of LifeMD.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

LFMD_IN_39 [2025-04-29 09:47:25 -0400] 126 Bytes | 29 tokens | Cum: 7990 tkns (99.88% of 8k)
==========================================================================

====================================
[2025-04-29 09:47:25] # Analysis Completed
Elapsed Time: 26.24 seconds